Oncology Institute, Inc. (TOI) Preferred Stock Liabilities (2020 - 2021)
Oncology Institute's (TOI) quarterly Preferred Stock Liabilities came in at $230.0 million in Q3 2021, up 767.68% YoY from $26.5 million in Q3 2020, and up 14.7% on a QoQ basis from $200.5 million in Q2 2021.
Oncology Institute, Inc. (TOI) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Oncology Institute (TOI) has 2 years of Preferred Stock Liabilities data on file, last reported at $230.0 million in Q3 2021.
- Quarterly Preferred Stock Liabilities rose 767.68% year-over-year to $230.0 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $230.0 million (up 767.68% YoY) and the FY2020 annual result came in at $230.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities rose to $230.0 million in Q3 2021, from $200.5 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $230.0 million in Q1 2020 to a low of $26.5 million in Q3 2020.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 230.00 Mn |
| Jun 30, 2021 | 200.53 Mn |
| Mar 31, 2021 | 206.65 Mn |
| Dec 31, 2020 | 230.00 Mn |
| Sep 30, 2020 | 26.51 Mn |
| Jun 30, 2020 | 205.91 Mn |
| Mar 13, 2020 | 230.00 Mn |